From its base in Valhalla, Tinkeso Therapeutics develops off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for cancers and autoimmune disorders. Formerly known as Akeso Therapeutics, the early-stage biotech combines native and engineered NKT programs, including a non-genome-edited CD7 CAR-iNKT therapy aimed at blood cancers and a native type III NKT approach for acute myeloid leukemia. Its proprietary expansion platform is designed to produce at least 100 doses of CAR-modified iNKT cells from a single donor leukopak.
Autolus TherapeuticsSpun out of University College London in 2014, Autolus Therapeutics develops programmed autologous CAR T-cell therapies for cancer and autoimmune diseases. The company combines T-cell programming with clinical development and a 70,000-square-foot commercial manufacturing facility in Stevenage, UK, and its pipeline includes obe-cel and other investigational therapies. Its long-running collaboration with UCL remains central to moving programs from the laboratory into clinical studies.GAITHERSBURG, MD
AdaptimmuneAdaptimmune develops engineered T-cell receptor (TCR) therapies designed to direct the immune system against cancer, with a particular focus on solid tumors. Based in Oxfordshire, the company has built its platform over more than 15 years to identify cancer targets, enhance T-cell receptor affinity and screen candidates for potential off-target binding.541714PHILADELPHIA, PA
Volta TherapeuticsVolta Therapeutics creates an automated, closed system cell therapy manufacturing technology that brings GMP suites directly to the clinic. The company provides capacity, automation, and customization through continuous manufacturing devices to facilitate streamlined GMP cell therapy manufacturing.MARS, PA
Innovative Cellular TherapeuticsHeadquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.ROCKVILLE, MD